Ashley Gallagher, MA

The expanded approval adds a self-administered autoinjector option and new label language tying LDL-C lowering to reduced cardiovascular risk.

Although DSCSA is often viewed as a regulatory burden, pharmacy leaders illustrate its necessity through harrowing case studies of supply chain failures.

Pharmacy leaders urge regional alliances, scalable clinical services, and data exchange to make pharmacist care reimbursable and routine.

Rural pharmacist explains how local pharmacies close care gaps in older, rural patients by improving vaccine access, education, and on-time immunizations.

Pharmacists must navigate peptide and GLP-1 compounding legally by understanding 503A vs 503B rules.

The academy's updated influenza guidance arrives days after a White House executive order narrowed the recommended childhood vaccine schedule.

Dispensary of Hope delivers donated medications to uninsured patients, cutting emergency room visits and redefining pharmacy’s role in access.

Pharmacies are expanding vaccine access for flu, COVID, and other shots while debunking safety myths and adding test-to-treat services to improve patient care.

Pharmacist-backed travel kit picks tackle motion sickness, dehydration, and stomach upsets for on-the-go relief.

The White House and the American Academy of Pediatrics leave pharmacists navigating 2 competing sets of vaccine guidance for the upcoming season.

A decades-long research effort in mRNA-produced licensed vaccines targets influenza, respiratory syncytial virus, cytomegalovirus, HIV, and cancer.

Data show possible but insignificant reduction in hypertensive disorders of pregnancy after periconceptional or first-trimester GLP-1 exposure.

Community pharmacists deliver travel vaccine clinics, navigate entry rules, and update routine shots with new guidance on polio, measles, and chikungunya.

Data on excess deaths in high-income countries show the male mortality disadvantage during COVID-19 is concentrated in the pandemic's earliest phase.

Counseling, team-based care, and tailored pharmacy interventions remain among the most effective tools against medication nonadherence in the United States.

The approval gives pharmacists a new, nonegg-based seasonal influenza option for adults 50 and older ahead of the 2026-2027 flu season.

Oveporexton, an oral orexin receptor 2 agonist, is the first medicine to restore orexin signaling rather than manage symptoms of the rare sleep disorder.

This medication is the first FDA-approved OTC innovation in the cold and flu category in 14 years.

A study finds treated diabetes prevalence climbs steadily for 5 years after antipsychotic start, even with brief exposure.

Results from a trial show injectable cabotegravir plus rilpivirine reduced viral rebound compared with daily oral therapy.

Community and independent pharmacists are beginning to test whether they can help fill the resulting gaps in medication management for older adults.

Centuries of vaccine science saved more lives than any other intervention, and pharmacists matter now more than ever.

The rapid-acting insulin aspart biosimilar adds a third interchangeable option to NovoLog, with implications for pharmacy dispensing and counseling.

A target trial emulation found early remdesivir initiation was associated with reduced 1-year risk of graft loss and cardiovascular events.

Every pattern of hormonal contraceptive use was associated with subsequent semaglutide initiation, a signal pharmacists and prescribers should watch for.

New survey data reveal information gaps in respiratory syncytial virus immunization decisions.

Voluntary licensing agreements covering 129 low- and middle-income countries arrive as phase 3 trials continue.

Large trial emulation study finds a 21% reduction in 3-year fracture risk compared with DPP-4 inhibitors, independent of weight loss or glycemic changes.

As extreme heat becomes more frequent, common prescription and OTC medications can raise a patient's risk of heat illness and sunburn.

Newly filed charters arrive as pharmacy groups already press HHS over similar changes to the CDC's vaccine advisory panel.